Switch to: References

Citations of:

Ethical Drug Development for Rare Childhood Diseases: When There Are Limited But Promising Data in Adults, How to Choose Between Safety or Efficacy Studies?

Liza-Marie Johnson, Devan M. Duenas & Benjamin S. Wilfond

American Journal of Bioethics 20 (4):111-113 (2020)

Add citations

You must login to add citations.

Flexibility Required: Balancing the Interests of Children and Risk in Drug Development for Rare Pediatric Conditions.Kathryn M. Porter, Anne Stevens & Benjamin S. Wilfond - 2020 - American Journal of Bioethics 20 (4):116-118.details Volume 20, Issue 4, May 2020, Page 116-118. Biomedical Ethics in Applied Ethics Direct download (2 more) Export citation Bookmark 1 citation
The Use of Pediatric Extrapolation to Avoid Unnecessary Pediatric Clinical Trials.Robert M. Nelson - 2020 - American Journal of Bioethics 20 (4):114-116.details Volume 20, Issue 4, May 2020, Page 114-116. Biomedical Ethics in Applied Ethics Direct download (2 more) Export citation Bookmark 1 citation
Clearing Muddy Waters: The Need to Reconceptualize Minor Increase over Minimal Risk in Pediatric Rare Disease Research.Devan M. Duenas, Benjamin S. Wilfond & Liza-Marie Johnson - 2020 - American Journal of Bioethics 20 (4):8-10.details Volume 20, Issue 4, May 2020, Page 8-10. Biomedical Ethics in Applied Ethics Direct download (2 more) Export citation Bookmark 1 citation

1